All In Biotech

Drug Trial Radar · NCT05419011

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

May 8, 2023

Primary completion

Jul 1, 2027

Study completion Jan 1, 2028

Sponsor

Sponsor type
NIH
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to other vaccines. Giving Tri-Ad5 in combination with immune enhancing N-803 may lower the chance of developing colon and other cancers in participants with Lynch syndrome.

Conditions

  • Colorectal Carcinoma
  • Colorectal Neoplasm
  • Lynch Syndrome

Interventions

  • Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5Biological

    Given SC

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • ColonoscopyProcedure

    Undergo SOC colonoscopy

  • Nogapendekin AlfaDrug

    Given nogapendekin alfa inbakicept (N-803) SC

  • Placebo AdministrationDrug

    Given SC

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancerTime frame: At 104 weeks

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • University of Arizona Cancer Center - Prevention Research Clinic

    Tucson, Arizona

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

  • Mayo Clinic in Rochester

    Rochester, Minnesota

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UT MD Anderson Cancer Center

    Houston, Texas

  • University of Puerto Rico

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.